Passive and active immunization against respiratory syncytial virus for the young and old
| Autor: | M. Pamela Griffin, Judith Falloon, Qing Zhu, Tonya Villafana, Mark T. Esser |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Palivizumab Time Factors Adolescent viruses Immunology Respiratory Syncytial Virus Infections Active immunization Virus Young Adult 03 medical and health sciences 0302 clinical medicine Pregnancy Drug Discovery Respiratory Syncytial Virus Vaccines Humans Medicine 030212 general & internal medicine Neutralizing antibody Maternal-Fetal Exchange Immunization Schedule Aged Pharmacology Attenuated vaccine Respiratory tract infections biology business.industry Vaccination Immunization Passive Infant Newborn Infant Middle Aged Virology Infectious Disease Transmission Vertical Respiratory Syncytial Viruses 030104 developmental biology Immunization Child Preschool biology.protein Molecular Medicine Female business Immunity Maternally-Acquired medicine.drug |
| Zdroj: | Expert Review of Vaccines. 16:737-749 |
| ISSN: | 1744-8395 1476-0584 |
| Popis: | Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is only one approved medicine to prevent RSV infections. Palivizumab, a monoclonal antibody (mAb) against the RSV fusion (F) protein, is indicated for preterm infants and children at high-risk for RSV infections. It is an active time in RSV vaccine and mAb development with 14 vaccines and 2 mAbs currently being tested in clinical trials as of 13 February 2017. Active vaccination of women in the third trimester or passive immunization of infants with a mAb are particularly attractive approaches as the most severe disease occurs within the first 6 months of life. Areas covered: Here, we review current approaches for preventing RSV in the young and old, describe proposed clinical endpoints for studies in pediatric and adult clinical trials and highlight results from recent and ongoing clinical studies. Expert commentary: With 16 candidates in clinical development, approval of the first RSV vaccine or mAb for the prevention of RSV in all infants or the elderly is likely to occur in the next five years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|